Tiansheng Pharmaceutical Group Co Ltd is a China-based company primarily engaged in drug R&D, production, sales, and the cultivation and processing of traditional Chinese medicinal materials. The Company's products include tablets, capsules, granules, teas, pills, and injections. Product varieties cover pediatrics, gynecology, cardiovascular system, digestive system, orthopedics, respiratory medicine, and anti-infective treatment areas. The Company's products are mainly sold to the domestic market.

Employees

1,273

Sector

Pharmaceuticals

Calendar

25/08 Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
21/08/26	CNY 5.300	0.00%	1,993,750
20/08/26	CNY 5.300	+0.76%	3,080,800
19/08/26	CNY 5.260	-2.95%	3,129,550
18/08/26	CNY 5.420	+1.88%	2,939,150
17/08/26	CNY 5.320	-0.56%	1,375,900

End-of-day quote Shenzhen S.E.

More quotes

End-of-day quote Shenzhen S.E. 21/08/2026			5-day change	1st Jan Change
5.300 ^CNY	0.00%		-0.75%	+9.05%

08/05	Tiansheng Pharmaceutical Secures Proposed Selection for Three Medicines in China's National Procurement	MT
29/04	Tiansheng Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

Market Cap	1.69B 251M 215M 201M 184M 345M 23.99B 350M 2.37B 926M 12.05B 941M 921M 39.86B	P/E 2024	-16.5x	P/E 2025	-27.9x
Enterprise Value	1.76B 262M 225M 210M 193M 361M 25.11B 366M 2.49B 969M 12.61B 985M 964M 41.72B	EV / Sales 2024	2.7x	EV / Sales 2025	3.16x
Free-Float	52.84%	Yield 2024 *	-	Yield 2025	-

08/05	Tiansheng Pharmaceutical Secures Proposed Selection for Three Medicines in China's National Procurement	MT
29/04	Tiansheng Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
29/04	Tiansheng Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
13/02	Three Tiansheng Pharma Drugs Set to Win Bids for China's Drug Procurement Program	MT
07/11	Tiansheng pharmaceutical and its controlling shareholder penalised, fined	RE
30/10/25	Tiansheng Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
14/10/25	Tiansheng Pharmaceutical Group Subsidiaries Tentatively Win Bulk Drug Tenders in Guangdong	MT
15/09/25	Tiansheng Pharmaceutical Gets China Supplementary Drug Approval for Sodium Bicarbonate Injection	MT
27/08/25	Tiansheng Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
29/04/25	Tiansheng Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
29/04/25	Tiansheng Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
10/02/25	Tiansheng Pharmaceutical Passes Consistency Evaluation for Antibiotic	MT
26/12/24	Chongqing Pharmaceutical Group Changsheng Pharmaceutical Co., Ltd announced that it expects to receive CNY 60 million in funding from C.Q. Pharmaceutical Holding Co., Ltd., Tiansheng Pharmaceutical Group Co., Ltd.	CI

1 week	-0.75%
Current month	+7.07%
1 month	+12.53%
3 months	-2.39%
6 months	+2.91%
Current year	+9.05%

Tiansheng Pharmaceutical Group Co., Ltd. Stock

Stocks

002872

CNE100002QC3

Pharmaceuticals

Valuation: Tiansheng Pharmaceutical Group Co., Ltd.

Chart: Tiansheng Pharmaceutical Group Co., Ltd.

Latest news : Tiansheng Pharmaceutical Group Co., Ltd.

Quotes and Performance

Course Extremes

Managers and Directors: Tiansheng Pharmaceutical Group Co., Ltd.

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

1 week	5.24	5.49
1 month	4.6	5.49
Current year	4.32	5.65
1 year	4.32	5.81
3 years	3.17	5.97
5 years	3.17	5.99
10 years	3.17	35.18

Manager	Title	Age	Since
Shuang Liu CEO	Chief Executive Officer	33	06/12/2018
Kai Sheng Wang DFI	Director of Finance/CFO	52	23/12/2013
Zonghua Tan PRN	Corporate Officer/Principal	54	11/12/2020

Director	Title	Age	Since
Shuang Liu CHM	Chairman	33	06/12/2018
Zonghua Tan BRD	Director/Board Member	54	11/12/2020
Dajian Yang BRD	Director/Board Member	66	11/12/2020

	2024	2025
Net sales	570M 84.75M 72.6M 67.93M 62.18M 117M 8.11B 118M 803M 313M 4.07B 318M 311M 13.47B	514M 76.47M 65.51M 61.29M 56.11M 105M 7.32B 107M 724M 282M 3.68B 287M 281M 12.16B
Net income	-87.4M -13M -11.14M -10.42M -9.54M -17.9M -1.24B -18.14M -123M -48.01M -625M -48.82M -47.76M -2.07B	-55.42M -8.24M -7.06M -6.61M -6.05M -11.35M -789M -11.5M -78.07M -30.45M -396M -30.96M -30.28M -1.31B
Net Debt	97.19M 14.46M 12.38M 11.59M 10.61M 19.91M 1.38B 20.17M 137M 53.39M 695M 54.29M 53.1M 2.3B	78.93M 11.74M 10.06M 9.41M 8.61M 16.17M 1.12B 16.38M 111M 43.36M 564M 44.09M 43.13M 1.87B

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
TIANSHENG PHARMACEUTICAL GROUP CO., LTD.	0.00%	-0.75%	+8.38%	+3.31%	251M
ELI LILLY AND COMPANY	+1.06%	+6.68%	+77.37%	+128.89%	1,109B
JOHNSON & JOHNSON	+1.53%	+4.27%	+51.72%	+62.22%	644B
ABBVIE INC.	+1.49%	+6.55%	+26.87%	+77.00%	463B
ROCHE HOLDING AG	+1.02%	+5.77%	+43.09%	+47.70%	371B
NOVARTIS AG	+0.85%	+4.07%	+23.88%	+41.58%	301B
ASTRAZENECA PLC	+1.26%	+6.81%	+1.59%	+14.67%	256B
AMGEN INC.	+1.72%	+5.57%	+48.20%	+68.14%	234B
NOVO NORDISK A/S	+1.59%	+2.09%	-15.52%	-52.29%	205B
GILEAD SCIENCES, INC.	+2.16%	+5.92%	+26.18%	+92.98%	178B
Average	+1.27%	+2.67%	+29.18%	+48.42%	376.13B
Weighted average by Cap.	+1.31%	+3.26%	+44.65%	+72.97%